Overview

A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)

Status:
RECRUITING
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety, of JYP0061 in acute NMOSD patients. The main questions it aims to answer are: efficacy and safety of JYP0061 in acute NMOSD patients. Participants will be treated with low-dose JYP0061 in combination with reduced dose glucocorticoids or standard dose glucocorticoids or high-dose JYP0061. Efficacy and safety evaluations will be conducted according to the protocol.
Phase:
PHASE2
Details
Lead Sponsor:
Guangzhou JOYO Pharma Co., Ltd
Treatments:
Glucocorticoids
Methylprednisolone
Prednisone